Aldo-keto reductase family 1 member C3 (AKR1C3) Is a biomarker and therapeutic target for castration-resistant prostate cancer

Molecular Medicine

Volumn 18, Issue 11, 2012, Pages

  Hamid, Agus Rizal A H ^a   Pfeiffer, Minja J ^a   Verhaegh, Gerald W ^a   Schaafsma, Ewout ^a   Brandt, Andre ^a   Sweep, Fred C G J ^a   Sedelaar, John P M ^a   Schalken, Jack A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; ONCOPROTEIN; UNCLASSIFIED DRUG;

BONE METASTASIS; BRAIN METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; DISEASE MARKER; DURA MATER; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; NOTE; PRIORITY JOURNAL; PROTEIN TARGETING; XENOGRAFT;

EID: 84872256884     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. ATCC catalog [Internet]. LGC standards [cited 01 May 2012]. Available at http://www.lgcstandardsatcc. org
2. Kogan I, et al. (2006) hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res. 66:3531-40.
3. Lee YG, et al. (2001) Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo. 15(2):157-62.
4. Pfeiffer MJ, Mulders PF, Schalken JA. (2010) An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate. 70:1524-32.
5. Klein KA, et al. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 3:402-8.